IRLAB Therapeutics AB Registered Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.03.21	IRRAS Announces the recruitment of Sten Gustafsson as Director of Investor Relations (PR Newswire)
09.03.21	First European patients dosed in IRLAB's Phase IIb/III mesdopetam study (PR Newswire)
09.03.21	IRRAS Announces the recruitment of Sten Gustafsson as Director of Investor Relations (PR Newswire)
09.03.21	First European patients dosed in IRLAB's Phase IIb/III mesdopetam study (PR Newswire)
08.12.20	IRLAB strengthens patent protection for Phase IIb/III drug candidate mesdopetam (PR Newswire)
08.12.20	IRLAB strengthens patent protection for Phase IIb/III drug candidate mesdopetam (PR Newswire)
01.10.20	IRLAB's mesdopetam IND accepted by the US FDA (PR Newswire)
01.10.20	IRLAB's mesdopetam IND accepted by the US FDA (PR Newswire)
23.09.20	IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market (PR Newswire)
23.09.20	IRLAB Therapeutics has been approved for listing on Nasdaq Stockholm Main Market (PR Newswire)
10.09.20	IRLAB's drug candidate pirepemat featured on cover of top-tier journal JPET (PR Newswire)
10.09.20	IRLAB's drug candidate pirepemat featured on cover of top-tier journal JPET (PR Newswire)
03.08.20	IRLAB's IRL752 is proposed pirepemat as a unique INN by WHO (PR Newswire)
03.08.20	IRLAB's IRL752 is proposed pirepemat as a unique INN by WHO (PR Newswire)
09.07.20	IRLAB's Clinical Drug Candidate IRL752 Published in JPET (PR Newswire)
09.07.20	IRLAB's Clinical Drug Candidate IRL752 Published in JPET (PR Newswire)
04.06.20	IRLAB's Phase IIb/III Study in Parkinson's disease to Target Good ON (PR Newswire)
04.06.20	IRLAB's Phase IIb/III Study in Parkinson's disease to Target Good ON (PR Newswire)
23.03.20	IRLAB's Phase IIa Study with IRL752 is Published in Movement Disorders (PR Newswire)
23.03.20	IRLAB's Phase IIa Study with IRL752 is Published in Movement Disorders (PR Newswire)
04.02.20	IRLAB's IRL790 Receives New Name `mesdopetam' (PR Newswire)
04.02.20	IRLAB's IRL790 Receives New Name `mesdopetam' (PR Newswire)
13.12.19	IRLAB Has Carried Out a Directed Issue of SEK 70 Million and Resolves on a Rights Issue of Approximately SEK 145 Million (PR Newswire)
13.12.19	IRLAB Has Carried Out a Directed Issue of SEK 70 Million and Resolves on a Rights Issue of Approximately SEK 145 Million (PR Newswire)
06.11.19	IRLAB's Drug Candidates IRL942 and IRL1009 Have Been Granted Patents in the US and Europe (PR Newswire)
06.11.19	IRLAB's Drug Candidates IRL942 and IRL1009 Have Been Granted Patents in the US and Europe (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Holcim	89.98	1.72 %	K V
Sonova Hldg	303.90	1.17 %	K V
Part Grp Hldg	1’222.50	1.12 %	K V
Lonza Grp	518.40	0.93 %	K V
Swiss Life Hldg	723.00	0.86 %	K V
Alcon	75.40	-0.26 %	K V
Roche Hldg G	249.40	-0.44 %	K V
Logitech Intl	68.46	-0.67 %	K V
Sika	229.80	-0.73 %	K V
Kuehne+Nagel Int	208.00	-1.14 %	K V

Nachrichten zu IRLAB Therapeutics AB Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten